ENABLING A PHARMACEUTICAL R&D PIPELINE
The pharmaceutical industry's lifeblood is R&D. A major drug company’s success almost completely depends on discovering and developing new medicines, and their capital investment reflects this. Pharmaceutical R&D spending is huge – the second largest of all industries – and it is expected to grow even more. This puts significant pressure on the industry to optimise R&D. However, traditional R&D approaches across the industry yield a low success rate and costs billions, which in-turn impacts the return on investment that goes into drugs discovery.
Can new approaches that use exploratory computer modelling help to identify efficiencies and improve the R&D process by predicting the pipeline of drugs in an effective way?
Using agent-based modelling techniques, we developed an advanced simulation environment that relies on the information about the chemical assets. The model accounts for assets that currently exist in GSK’s R&D pipeline, and predicts future compounds with varying attributes. We have provided an extremely adaptable interface, which allows GSK to tailor model runs to the specific attributes of interest and create new modelled compounds. The user can run a range of scenarios in order to generate a compelling business case for potential R&D strategies. This includes different progression strategies, such as fast tracked and accelerated, and their impact on cost and ROI. It handles uncertainty throughout the multiple stages and also in consumer demand for compounds.
Send us an email, to discuss a new project.
We’re a team of innovators who are excited about unique ideas and help companies to create amazing solutions.